Chronic Kidney Disease Treatment

Global Chronic Kidney Disease Treatment Market to Reach US$17.2 Billion by 2030

The global market for Chronic Kidney Disease Treatment estimated at US$14.5 Billion in the year 2024, is expected to reach US$17.2 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$10.9 Billion by the end of the analysis period. Growth in the Dialysis segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 5.4% CAGR

The Chronic Kidney Disease Treatment market in the U.S. is estimated at US$4.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Chronic Kidney Disease Treatment Market – Key Trends & Drivers Summarized

Why Is Chronic Kidney Disease Emerging as a High-Priority Global Health Burden?
Chronic Kidney Disease (CKD) is becoming an increasingly urgent public health concern, affecting over 850 million individuals worldwide and ranking among the top causes of mortality and disability-adjusted life years. The disease’s strong association with diabetes, hypertension, and cardiovascular disorders—coupled with rising aging populations—continues to drive its global prevalence. As early-stage CKD often remains asymptomatic, late diagnosis and progression to end-stage renal disease (ESRD) impose substantial clinical and economic burdens on healthcare systems, requiring long-term dialysis or organ transplantation.

Governments and health agencies are prioritizing CKD within noncommunicable disease (NCD) strategies due to its chronic trajectory, high treatment costs, and impact on workforce productivity. The shift toward preventive nephrology and early intervention is reinforcing demand for treatment modalities that delay disease progression, manage comorbidities, and reduce complications such as anemia, hyperphosphatemia, and mineral bone disorders. Public awareness campaigns and screening programs are also expanding, particularly in high-risk populations, to promote earlier diagnosis and engagement with treatment pathways.

How Are Pharmacological Advancements and Multi-Target Therapies Shaping CKD Treatment Approaches?
Pharmacological innovation is reshaping the CKD treatment paradigm, with a strong pipeline of novel agents that target disease-modifying pathways rather than solely managing symptoms. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have gained prominence not only for their glycemic control but also for their renal-protective and cardiovascular benefits in both diabetic and non-diabetic CKD populations. These agents, along with nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and endothelin receptor antagonists, are broadening therapeutic options beyond traditional ACE inhibitors and ARBs.

Combination therapies are increasingly being deployed to address the multifactorial nature of CKD progression, including inflammation, oxidative stress, and proteinuria. Meanwhile, the development of next-generation anemia treatments—such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs)—is enhancing outcomes for CKD-related anemia without the risks associated with erythropoiesis-stimulating agents. This multi-target approach is advancing CKD care toward more personalized and disease-specific regimens that emphasize renal function preservation and long-term risk reduction.

Which Delivery Models and Technologies Are Supporting Access and Continuity of CKD Care?
As healthcare systems prioritize early-stage CKD management, integrated care delivery models involving primary care, nephrology, nutrition, and behavioral health are gaining traction. These multidisciplinary programs aim to slow disease progression and optimize management of cardiovascular comorbidities through coordinated, protocol-driven interventions. Dialysis centers are also evolving to offer home-based peritoneal dialysis and hemodialysis options, supporting patient autonomy and reducing the logistical burden on facility-based care infrastructure.

Digital health tools—such as remote monitoring platforms, electronic health records with predictive analytics, and tele-nephrology—are improving continuity of care across geographies. These technologies enable early detection of functional decline, real-time medication adherence monitoring, and timely therapeutic adjustments. In resource-limited settings, mobile health (mHealth) apps and portable diagnostic devices are extending access to nephrology care and education, especially in rural and underserved populations where nephrologist shortages are acute.

How Are Payers and Policymakers Addressing the High Economic Burden of CKD Treatment?
CKD imposes one of the highest per-patient healthcare costs globally, particularly in its late stages where dialysis and transplantation dominate expenditures. As ESRD rates climb, public and private payers are reevaluating reimbursement frameworks to incentivize early intervention, promote cost-effective therapies, and delay dialysis initiation. Bundled payment models and value-based care contracts are being piloted to align provider incentives with patient outcomes in CKD management.

Policy measures are also expanding access to essential medicines, including the inclusion of newer agents in national formularies and reimbursement schemes. In some regions, governments are investing in CKD registries, risk stratification tools, and quality metrics to improve care oversight and resource allocation. Cross-sector collaboration with patient advocacy groups and pharmaceutical manufacturers is supporting medication affordability programs and public education initiatives—aimed at shifting CKD from a silent epidemic to a proactively managed chronic disease.

Can the Chronic Kidney Disease Treatment Market Drive Outcome-Centric Innovation While Addressing Global Disparities?
The path forward for CKD treatment lies in balancing innovation with equity—ensuring that novel therapies, diagnostic tools, and multidisciplinary care frameworks reach patients across all economic strata and healthcare systems. As treatment protocols become more sophisticated and data-driven, healthcare stakeholders must address persistent gaps in access, especially in low- and middle-income countries where diagnosis rates remain low and renal replacement therapies are unaffordable for most.

Achieving sustainable impact will require investment in workforce training, digital infrastructure, public health surveillance, and policy reform. As clinical evidence grows for renal-protective therapies and holistic disease management models, the central question emerges: Can the global CKD treatment market scale equitable, outcome-oriented care fast enough to mitigate long-term human and financial costs—while adapting to emerging science, demographic shifts, and system-level pressures?

SCOPE OF STUDY:

The report analyzes the Chronic Kidney Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Drug Type, Dialysis); End-Use (Hospitals & Clinics, Dialysis Centers, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Allena Pharmaceuticals
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Cincor Pharma, Inc.
• DiaMedica Therapeutics Inc.
• Eli Lilly and Company
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline plc
• Kibow Biotech, Inc.
• Lexicon Pharmaceuticals, Inc.
• Monogram Health
• Novo Nordisk A/S
• ProKidney Corp.
• Reata Pharmaceuticals, Inc.
• Sanofi S.A.
• Strive Health

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.